APO (Shanghai) Biotechnology

APO (Shanghai) Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative oncology therapeutics. The company specializes in developing small molecule inhibitors and monoclonal antibodies targeting key pathways in cancer progression, such as the PD-1/PD-L1 axis and angiogenesis. APO Biotechnology aims to address unmet medical needs in prevalent cancers including lung, liver, and gastric malignancies. Their research and development efforts are centered on creating high-efficacy, low-toxicity treatments through rigorous preclinical validation and strategic clinical trial design.